farglitazar has been researched along with Cirrhosis, Liver in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byrjalsen, I; Christiansen, C; Gardner, S; Goodman, Z; Henriksen, K; Karsdal, MA; Krag, A; Leeming, DJ; Nielsen, MJ; Patel, K; Schuppan, D | 1 |
| Brigandi, R; Chuang, WL; Gardner, S; Goodman, Z; Husa, P; Jonas, M; Levine, R; Makhlouf, H; McHutchison, J; Patel, K; Rockey, D; Rodriguez-Torres, M; Schultz, M; Shiffman, M; Stancil, B; Theodore, D; Watson, H; Webster, A | 1 |
2 trial(s) available for farglitazar and Cirrhosis, Liver
| Article | Year |
|---|---|
Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy.
Topics: Biomarkers; Collagen Type III; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Oxazoles; Patient Selection; Quinazolines; Thiazolidinediones; Tyrosine | 2016 |
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.
Topics: Adult; Aged; Biopsy; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Oxazoles; PPAR gamma; Tyrosine | 2010 |